Dilip Shanghvi is the founder and managing director of Sun Pharmaceutical Industries Limited. Sun Pharma was founded in 1983 and it is currently the largest drugmaker in India. Appreciation of the Sun Pharma stock led to a 50% surge in his personal wealth, amounting to USD 4.7 billion. Sanghvi is now the third richest Indian pushing the IT czar Azim Premji to the 4th spot.
Shanghvi is also the Chairman and Managing Director of Sun Pharmaceutical Advanced Research Company Ltd. (SPARC Ltd.); an International pharmaceutical company engaged in research and development of drugs and delivery systems. SPARC, created in 2007 by the de-merger of innovative business from Sun Pharma, is the first pure-RD company to be listed on the Indian stock exchanges.
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) is a multinational pharmaceutical company headquartered in Mumbai, Maharashtra that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. The company offers formulations in various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology. It also provides APIs such as warfarin, carbamazepine, etodolac, and clorazepate, as well as anticancers, steroids, peptides, sex hormones, and controlled substances.